TY - JOUR
AU - Morales, Daniel R.
AU - Conover, Mitchell M.
AU - You, Seng Chan
AU - Pratt, Nicole
AU - Kostka, Kristin
AU - Duarte-Salles, Talita
AU - Fernández-Bertolín, Sergio
AU - Aragón, María
AU - DuVall, Scott L.
AU - Lynch, Kristine E.
AU - Falconer, Thomas
AU - van Bochove, Kees
AU - Sung, Cynthia
AU - Matheny, Michael E.
AU - Lambert, Christophe G.
AU - Nyberg, Fredrik
AU - Alshammari, Thamir M.
AU - Williams, Andrew E.
AU - Park, Rae Woong
AU - Weaver, James
AU - Sena, Anthony G.
AU - Schuemie, Martijn J.
AU - Rijnbeek, Peter R.
AU - Williams, Ross D.
AU - Lane, Jennifer C. E.
AU - Prats-Uribe, Albert
AU - Zhang, Lin
AU - Areia, Carlos
AU - Krumholz, Harlan M.
AU - Prieto-Alhambra, Daniel
AU - Ryan, Patrick B.
AU - Hripcsak, George
AU - Suchard, Marc A.
PY - 2020
DA - December
TI - Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
JO - The Lancet Digital Health
EP - 114
VL - 3
IS - 2
DO - https://doi.org/10.1016/S2589-7500(20)30289-2
AB - Background: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been postulated to affect susceptibility to COVID-19. Observational studies so far have lacked rigorous ascertainment adjustment and international generalisability. We aimed to determine whether use of ACEIs or ARBs is associated with an increased susceptibility to COVID-19 in patients with hypertension.
PB - Elsevier
UR - https://discovery.dundee.ac.uk/en/publications/f2a323b3-b55d-4dd3-8d6b-4a4532edac80
KW - Coronavirus (COVID-19)
ER